Stifel projected that the 15-day sensor could enhance DexCom’s gross margin in 2026, potentially contributing to year-over-year EBITDA margin expansion. The firm acknowledged certain risks, including ...

If you have suffered a loss on your DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DCXM) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at [email protected], or fill out ...

Lead Plaintiff Deadline is December 26, 2025 NEW YORK, Nov. 11, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds  investors that ...

On March 7, 2025, DexCom disclosed in a filing with the U.S. Securities and Exchange Commission ("SEC"), that, three days earlier, it had received a warning letter from the U.S. Food and Drug ...

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ:DXCM) securities during ...

Bullish option flow detected in DexCom (DXCM) with 4,618 calls trading, 1.3x expected, and implied vol increasing almost 3 points to 63.76%. Dec-25 85 calls and 10/24 weekly 73 calls are the most ...

RBC Capital lowered the firm’s price target on DexCom (DXCM) to $85 from $100 but keeps an Outperform rating on the shares. The market misunderstood the conservative initial 2026 guide, which likely ...

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the“Company”) (NASDAQ: ...

As of October 30, 2025, the average one-year price target for DexCom is $102.13/share. The forecasts range from a low of $85.07 to a high of $126.00. The average price target represents an increase of ...